De-escalation of biological therapy in Inflammatory bowel disease (IBD) and outcomes at week 52: a single centre experience

被引：0
|
作者：
Al-Talib, Ismaeel [1 ]
Iqbal, Majid [1 ]
Shaheen, Sirah [1 ]
Shingadia, Maya [1 ]
Slater, Jayne [1 ]
King, Dominic [1 ]
Rattehalli, Deepa [1 ]
De Silva, Shanika [1 ]
机构：
[1] Dudley Grp NHS Fdn Trust, Dudley, England
来源：
GUT | 2023年 / 72卷 / SUPPL_2期
关键词：
D O I：
10.1136/gutjnl-2023-BSG.132
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P60
引用
收藏
页码：A79 / A79
页数：1
相关论文
共 50 条
  • [41] Disparities in biologic therapy for inflammatory bowel disease: results from a tertiary referral IBD centre
    Wong, Charlotte
    Kamperidis, Nikolaos
    Younge, Lisa
    Chana, Angela
    Arebi, Naila
    GUT, 2023, 72 (SUPPL_2) : A77 - A77
  • [42] Need for anti-TNF escalation in Inflammatory Bowel Disease - A single center experience
    Fernandes, S.
    Moura, C.
    Santos, P.
    Sousa, P.
    Correia, L.
    Moura Santos, P.
    Valente, A.
    Rita Goncalves, A.
    Baldaia, C.
    Fatela, N.
    Serejo, F.
    Velosa, J.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S336 - S337
  • [43] De-escalation from dose-intensified antitumor necrosis factor therapy is successful at 12 months in most patients with inflammatory bowel disease
    Chu, I.
    Little, R.
    Ward, M.
    Sparrow, M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 126 - 127
  • [44] INFLAMMATORY BOWEL DISEASE (IBD) IN PATIENTS WITH AUTOIMMUNE SCLEROSING CHOLANGITIS COMMONLY REQUIRES ESCALATION OF IBD THERAPY HOWEVER CO-EXISTENT IBD DOES NOT AFFECT LIVER RELATED OUTCOMES
    Nayagam, Jeremy
    Mandour, Omer
    Graham, Jonathon
    Hayee, Bu
    Dubois, Patrick
    Bjarnason, Ingvar
    Sanchez-Fueyo, Alberto
    Heneghan, Michael A.
    Kent, Alexandra
    Samyn, Marianne
    Joshi, Deepak
    HEPATOLOGY, 2019, 70 : 861A - 861A
  • [45] Hospital readmissions in patients with inflammatory bowel disease: A UK single centre experience
    Chan, L.
    Wood, E.
    Fang, L.
    Limdi, J.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S354 - S355
  • [46] OUTCOMES FOLLOWING ANTI-TNF DISCONTINUATION AND THE RISK OF RELAPSE IN INFLAMMATORY BOWEL DISEASE; A SINGLE CENTRE EXPERIENCE
    Coffey, L.
    Mullen, A.
    Leyden, J.
    MacMathuna, P.
    GUT, 2017, 66 : A2 - A2
  • [47] EFFICACY OF HIGH AND LOW DOSE ORAL VITAMIN D REPLACEMENT THERAPY IN INFLAMMATORY BOWEL DISEASE (IBD): SINGLE CENTRE COHORT
    Hiew, H. J.
    Naghibi, M.
    Wu, J.
    Saunders, J.
    Cummings, F.
    Smith, T. R.
    GUT, 2013, 62 : A2 - A2
  • [48] Inflammatory bowel disease and depressive symptoms: the prevalence and factors associated with depression in patients with inflammatory bowel disease on intravenous biological therapy - single center experience
    Smolovic, B.
    Lukic, M.
    Bojovic, S.
    Vukovic, M. N.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (11) : 4008 - 4016
  • [49] Frequency and effectiveness of dose escalation of biologic therapy in Inflammatory Bowel Disease: The RAINBOW-IBD study of ENEIDA
    Rubin De Celix, C.
    Ricart, E.
    Martin-Arranz, M. D.
    Perez-Martinez, I.
    Barrio, J.
    Mesonero, F.
    Gomollon, F.
    de Castro, L.
    Ramos, L.
    Garcia-Lopez, S.
    Arias, L.
    Manosa, M.
    Iglesias, E.
    Calvet, X.
    Pascual, I.
    Casanova, M. J.
    Perez-Calle, J. L.
    Giordano, A.
    Sierra, M.
    Vera, I.
    Navarro-Llavat, M.
    Lorente, R.
    Piqueras, M.
    Rivero, M.
    Guardiola, J.
    Esteve, M.
    Fuentes Coronel, A.
    Rodriguez-Lago, I.
    Ponferrada, A.
    Ber, Y.
    Tardillo, C.
    Marquez, L.
    Carpio, D.
    Taxonera, C.
    Bermejo, F.
    Busquets, D.
    Camps, B.
    Domenech, E.
    Chaparro, M.
    Gisbert, J. P.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I210 - I212
  • [50] More Biologics, More Problems? Dual Biologic Therapy in Inflammatory Bowel Disease Arthropathy: A Single Centre Experience
    Rininsland, Vanessa
    Reis, Jodie
    JOURNAL OF RHEUMATOLOGY, 2020, 47 (07) : 1046 - 1047
12345